Effects of prostaglandin E1, melatonin, and oxytetracycline on lipid peroxidation, antioxidant defense system, paraoxonase (PON1) activities, and homocysteine levels in an animal model of spinal cord injury

Spine

Volumn 28, Issue 15, 2003, Pages 1643-1652

  Topsakal, Cahide ^a   Kilic, Nermin ^a   Ozveren, Faik ^a   Akdemir, Ismail ^a   Kaplan, Metin ^a   Tiftikci, Murat ^a   Gursu, Ferit ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

Antioxidant drugs; Homocysteine; Lipid peroxidation; Paraoxonase; Spinal cord injury

Indexed keywords

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; GLUTATHIONE PEROXIDASE; HOMOCYSTEINE; MALONALDEHYDE; MELATONIN; OXYTETRACYCLINE; PRIMAMYCIN; PROSTAGLANDIN E1; PROSTAVASIN; SUPEROXIDE DISMUTASE;

ARTICLE; BLOOD LEVEL; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVITY; LAMINECTOMY; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SPINAL CORD INJURY; STATISTICAL ANALYSIS;

EID: 0042074511     PISSN: 03622436     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.BRS.0000083163.03910.B1     Document Type: Article

References (109)

1. Bulkley GB. The role of oxygen free radicals in human disease processes. Surgery 1983;94:407-11.
2. Halliwell B, Gutteridge JM. Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch Biochem Biophys 1986;246:501-14.
3. Ulakoglu EZ, Saygi A, Gumustas MK, et al. Alterations in superoxide dismutase activities, lipid peroxidation and glutathione levels in thinner-inhaled rat lung: relationship between histopathological properties. Pharmacol Res 1998;38:209-14.
4. Gorgulu A, Kiris T, Unal F, et al. Superoxide dismutase activity and the effects of NBQX and CPP on lipid peroxidation in experimental spinal cord injury. Res Exp Med 2000;199:285-93.
5. Oyanagui Y. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal Biochem 1984;142:290-6.
6. Avissar N, Whitin JC, Allen PZ, et al. Antihuman plasma glutathione peroxidase antibodies: immunologic investigations to determine plasma glutathione peroxidase protein and selenium content in plasma. Blood 1989;73:318-23.
7. Ferrari R, Ceconi C, Curello S, et al. Oxygen free radicals and myocardial damage: protective role of thiol-containing agents. Am J Med 1991;91(suppl 3C):95S-105S.
8. Wendel A. Glutathione peroxidase. In: Jakoby WB, Bend JR, Caldwell J, eds. Enzymatic Basis of Detoxication. New York, NY: Academic Press; 1980:333-48.
9. Coppola A, Davi G, De Stefano V, et al. Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost 2000;26:243-54.
10. Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocystinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J 1997;11:1157-68.
11. Kuo CL, La Du BN. Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. Drug Metab Dispos 1998;26:653-60.
12. Blatter Garin M-C, James RW, Dussoix P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified concentrations of the enzyme. J Clin Invest 1997;99:62-6.
13. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998;31:329-36.
14. Hegele RA. Paraoxanase genes and disease. Ann Med 1999;31:217-24.
15. Misra HP. Generation of superoxide free radical during the autoxidation of thiols. J Biol Chem 1974;249:2151-5.
16. Rowley DA, Halliwell B. Superoxide dependent formation of hydroxyl radicals in the presence of thiol compounds. FEBS Lett 1982;138:33-6.
17. Demediuk P, Saunders RD, Anderson DK, et al. Membrane lipid changes in laminectomized and traumatized cat spinal cord. Proc Natl Acad Sci USA 1985;82:7071-5.
18. Faden AI, Ellison JA, Noble LJ. Effects of competitive and non-competitive NMDA receptor antagonists in spinal cord injury. Eur J Pharmacol 1990;175:165-74.
19. Kaptanoglu E, Tuncel M, Palaoglu S, et al. Comparison of the effects of melatonin and methylprednisolone in experimental spinal cord injury. J Neurosurg 2000;93(suppl 1):77-84.
20. Kunihara T, Sasaki S, Shiiya N, et al. Lazaroid reduces production of IL-8 and IL-1 receptor antagonist in ischemic spinal cord injury. Ann Thorac Surg 2000;69:792-8.
21. Saunders RD, Dugan LL, Demediuk P, et al. Effects of methylprednisolone and the combination of α-tocopherol and selenium on arachidonic acid metabolism and lipid peroxidation in traumatized spinal cord tissue. J Neurochem 1987;49:24-31.
22. Siegal T, Siegal T, Lossos F. Experimental neoplastic spinal cord compression: effect of anti-inflammatory agents and glutamate receptor antagonists on vascular permeability. Neurosurgery 1990;26:967-70.
23. Topsakal C, Erol FS, Ozveren MF, et al. Effects of methylprednisolone and dextromethorphan on lipid peroxidation in an experimental model of spinal cord injury. Neurosurg Rev 2002;25:258-66.
24. Topsakal C, Kilic N, Erol FS, et al. Medroxyprogesterone acetate, enoxaparin, and pentoxifylline cause alterations in lipid peroxidation, paraoxonase (PON1) activities, and homocysteine levels in the acute oxidative stress in an experimental model of spinal cord injury. Acta Neurochirurgica (Wien) 2002;144:1021-31.
25. Dutta-Roy AK, Kahn NN, Sinha AK. Prostaglandin E1: the endogenous physiological regulator of platelet mediated blood coagulation. Prostaglandins Leukot Essent Fatty Acids 1989;35:189-95.
26. Ernoffson M, Thelin S, Siegbahn A. Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study. J Thorac Cardiovasc 1997;113:576-84.
27. Grabitz K, Freye E, Prior R, et al. Does prostaglandin E1 and superoxide dismutase prevent ischaemic spinal cord injury after thoracic aortic cross-clamping? Eur J Vasc Surg 1990;4:19-24.
28. Kozek-Langenecker SA, Wanzel O, Berger R, et al. Increased anticoagulation during cardiopulmonary bypass by prostaglandin E1. Anesth Analg 1998;87:985-8.
29. Nieuwland R, Berckmans RJ, Rotteveel-Eijkmann RC, et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 1997;96:3534-41.
30. Ohnishi ST, Sakamoto A, Ohnishi T, et al. Inhibition of lipid peroxidation by prostaglandin oligomeric derivates. Prostaglandins Leukot Essent Fatty Acids 1992;45:217-21.
31. Tsuji T, Matsuyama Y, Sato K, et al. Evaluation of spinal cord blood flow during prostaglandin E1-induced hypotension with power doppler ultrasonography. Spinal Cord 2001;39:31-6.
32. Abe M, Reiter RJ, Orhii PB, et al. Inhibitory effect of melatonin on cataract formation in newborn rats: evidence for an antioxidant role for melatonin. J Pinela Res 1994;17:94-100.
33. Antolin I, Rodrigues C, Sainz RM, et al. Neurohormone melatonin prevents cell damage: effect on gene expression for antioxidant enzymes. FASEB J 1996;10:882-90.
34. Barlow-Walden L, Reiter RJ, Abe M, et al. Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int 1995;26:497-502.
35. Fujimoto T, Nakamura T, Ikeda T, et al. Potent protective effects of melatonin on experimental spinal cord injury. Spine 2000;25:769-75.
36. Giusti P, Lipartiti M, Gusella M, et al. In vitro and in vivo protective effects of melatonin against glutamate oxidative stress and neurotoxicity. Ann NY Acad Sci 1997;825:79-84.
37. Kotler M, Rodriguez C, Sainz RM, et al. Melatonin increases gene expression for antioxidant enzymes in rat brain cortex. J Pineal Res 1998;24:83-9.
38. Kriegsfield LJ, Drazen DL, Nelson RJ. In vitro melatonin treatment enhances cell-mediated immune function in male prairic voles (Microtus ochrogaster). J Pineal Res 2001;30:193-8.
39. Melchiori D, Reiter RJ, Sewerynek E, et al. Melatonin reduces kainate-induced lipid peroxidation in homogenates of different brain regions. FASEB J 1995;9:1205-10.
40. Mesenge C, Margaill I, Verrecchia C, et al. Protective effect of melatonin in a model of traumatic brain injury in mice. J Pineal Res 1998;25:41-6.
41. Persengiev SP. The neuroprotective and antiapoptotic effects of melatonin in cerebellar neurons involve glucocorticoid receptor and p130 signal pathways. J Steroid Biochem Mol Biol 2001;77:151-8.
42. Pieri C, Marra M, Moroni F, et al. Melatonin: a peroxyl radical scavenger more effective than vitamin E. Life Sci 1994;55:PL271-6.
43. Regrigny O, Delagrange P, Scalbert E, et al. Melatonin improves cerebral circulation security margin in rats. Am J Physiol 1998;275:H139-44.
44. Tan DX, Chen LD, Poeggeler B, et al. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1993;1:57-60.
45. Taskiran D, Tanyalcin T, Sozmen EY, et al. The effects of melatonin on the antioxidant systems in experimental spinal injury. Int J Neurosci 2000;104:63-73.
46. Clark WM, Calcagno FA, Gabler WL, et al. Reduction of central nervous system reperfusion injury in rabbits using doxycycline treatment. Stroke 1994;25:1411-6.
47. Gabler WL, Creamer HR. Suppression of human neutrophil functions by tetracyclines. J Periodontal Res 1991;26:52-8.
48. Lauhio A, Salo T, Ding Y, et al. In vivo inhibition of human neutrophil collagenase (MMP-8) activity during long-term combination therapy of doxycycline and non-steroidal anti-inflammatory drugs (NSAID) in acute reactive arthritis. Clin Exp Immunol 1994;98:21-8.
49. Matsuo Y, Onodera H, Shiga Y, et al. Role of cell adhesion molecules in brain injury after transient middle cerebral artery occlusion in the rat. Brain Res 1994;656:344-52.
50. Reasoner DK, Hindman BJ, Dexter F, et al. Doxycycline reduces early neurologic impairment after cerebral arterial air embolism in the rabbit. Anesthesiology 1997;87:569-76.
51. Skakun NP, Vysotskii II. Effect of tetracycline antibiotics on lipid peroxidation. Antibiotiki 1982;27:684-7.
52. Sundrehagen E. Axis Biochemicals ASA. Enzymatic Assay for Homocysteine and a Kit Therefor. EP 623174/US5631127.
53. Tikka TM, Koistinaho JE. Minocycline provides neuroprotection against n-methyl-d-aspartate neurotoxicity by inhibiting microglia. J Immunol 2001;16:7527-33.
54. Principles of Laboratory Animal Care. NIH Publication No. 86-23; revised 1985.
55. Rivlin AS, Tator CH. Effect of duration of acute spinal cord compression in a new acute cord injury model in the rat. Surg Neurol 1978;10:39-43.
56. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
57. Satoh K. Serum lipoperoxides in cerebrovascular disorders determined by colorimetric method. Clin Chim Acta 1978;90:37-43.
58. Yagi K. Assay for plasma lipid peroxides. Methods Enzymol 1984;109:328-31.
59. Fairbanks VF, Klee GG. Biochemical aspect of hematology. In: Burtis CA, Ashwood ER, eds. Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia, PA: Saunders; 1999:1642-710.
60. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70:158-68.
61. Eckerson HW, Romson J, Wyte C, et al. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 1983;35:214-27.
62. Frantzen F, Faaren AL, Alfheim I, et al. An enzyme conversion immunoassay for determining total homocysteine in plasma of serum. Clin Chem 1998;44:311-6.
63. Di Monno G, Coppola A, Mancini FP, et al. Homocysteine, platelet function and thrombosis. Haematologica 1999;84:61-3.
64. Halvorsen B, Brude I, Drevon CA, et al. Effect of homocysteine on copper ion-catalyzed, azo compound-initiated, and mononuclear cell-mediated oxidative modification of low density lipoprotein. J Lipid Res 1996;37:1591-600.
65. Aviram M, Fuhrman B. LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of pro-oxidants vs. antioxidants. Mol Cell Biochem 1998;188:149-59.
66. Malin R, Laine S, Rantalaiho V, et al. Lipid peroxidation is increased in paraoxonase 155 homozygotes compared with m-allele carriers. Free Radic Res 2001;34:477-84.
67. Jakubowski H, Ambrosius WT, Pratt JH. Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Lett 2001;492:35-9.
68. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. J Biol Chem 2000;11:3957-62.
69. Sozmen B, Delen Y, Girgin FK, et al. Catalase and paraoxonase in hypertensive type 2 diabetes mellitus: correlation with glycemic control. Clin Biochem 1999;32:423-7.
70. Ayub A, Mackness MI, Arrol S, et al. Serum paraoxonase after myocardial infarction. Arteroscler Thromb Vasc Biol 1999;19:330-5.
71. Paragh G, Seres I, Balogh Z, et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 1998;80:166-70.
72. Schmidt R, Scmidt H, Fazekas F, et al. MRI cerebral white matter lesions and paraoxonase PON1 polymorphism. Three-year follow-up of the Austrian Stroke prevention study. Arterioscler Tromb Vasc Biol 2000;20:1811-6.
73. Furlong CE, Li W-F, Shih DM, et al. Genetic and temporal determinants of pesticide sensitivity: role of paraoxonase (PON1). Neurotoxicology 2000;21:91-100.
74. Oda MN, Bielicki JK, Berger T, et al. Cysteine substitution in apolipoprotein A-1 primary structure modulate paraoxonase activity. Biochemistry 2001;40:1710-8.
75. Kudchodkar BJ, Lacko AG, Dory L, et al. Dietary far modulates serum paraoxonase 1 activity in rats. J Nutr 2000;130:2427-33.
76. Hernanz A, Plaza A, Martin-Mola E, et al. Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women. Clin Biochem 1999;32:65-70.
77. Brattstrom I, Lindgren A. Hyperhomocystinemia as a risk factor for stroke [review]. Neurol Res 1992;14(suppl 2):81-4.
78. Curtis D, Sparow R, Brennan L, et al. Elevated serum homocysteine as a predictor for vitamin B12 or folate deficiency. Eur J Haematol 194;52:227-32.
79. Hermann W, Schorr H, Purschwitz K, et al. Total homocysteine, vitamin B(12), and total antioxidant status in vegetarians. Clin Chem 2001;47:1094-101.
80. Jacobsen DW, Gatautis VJ, Green R, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem 1994;40:873-81.
81. Nilsson K, Gustafson L, Faldt R, et al. Hyperhomocystinemia - a common finding in a psychogeriatric population. Eur J Clin Invest 1996;26:853-9.
82. Chao CL, Kuo TL, Lee YT. Effects of methionine-induced hyperhomocystinemia on endothelium-dependent vasodilatation and oxidative status in healthy adults. Circulation 2000;101:485-90.
83. Massy ZA, Ceballos I, Chadefaux-Vekemens B, et al. Homocysteine, oxidative stress, and endothelium function in uremic patients. Kidney Int Supp 2001;78:S243-5.
84. Stamler JS, Loscalzo J. Endothelium-derived relaxing factor modulates the atherothrombogenic effects of homocysteine. J Cardiovasc Pharm 1992;20: S202-4.
85. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986;77:1909-16.
86. Mudd SH, Levy HL, Skovby F. Disorders of transulphuration. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. Metabolic Basis of Inherited Disease. 7th ed. New York, NY: McGraw-Hill; 1995:1279-327.
87. Bas Leerink C, van Ham DFJ, Heeres A, et al. Sulfhydryl compounds influence immunoreactivity, structure and functional aspect of lipoprotein (a). Thromb Res 1994;74:219-32.
88. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the bonding of lipoprotein (a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992;89:10193-7.
89. Jones BG, Rose FA, Tudball N. Lipid peroxidation and homocysteine induced toxicity. Atherosclerosis 1994;105:165-70.
90. Lynch SM, Frei B. Physiological thiol compounds exert pro-and antioxidant effects, respectively, on iron-and copper-dependent oxidation of human low-density lipoprotein. Biochem Biophys Acta 1997;1345:215-21.
91. Rafter GW. Plasma thiols, copper and rheumatoid arthritis. Med Hypotheses 1994;43:59-61.
92. Bleich S, Spilker K, Kurth C, et al. Oxidative stress and an altered methionine metabolism in alcoholism. Neuroscience Lett 2000;286:171-4.
93. Lipton SA, Kim W-K, Choi Y-B, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 1997;94:5923-8.
94. White AR, Huang X, Jobling MF, et al. Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's type neurodegenerative pathways. J Neurochem 2001;76:1509-20.
95. Zhang C, Cai Y, Adachi MT, et al. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem 2001;276:35867-74.
96. El Kossi M, Zakhary MM. Oxidative stress in the context of acute cerebrovascular stoke. Stroke 2000;31:1889-92.
97. Shih DM, Gu L, Hama S, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996;97:1630-9.
98. Nishio E, Watanebe Y. Homocysteine as a modulator of platelet-derived growth factor action in vascular smooth muscle cells: a possible role for hydrogen peroxide. Br J Pharmacol 1997;122:269-74.
99. Outinen PA, Sood SK, Liaw PC, et al. Characterization of the stress-inducing effects of homocysteine. Biochem J 1998;332:213-21.
100. Yamamoto M, Hara H, Adachi T. Effects of homocysteine on the binding of extracellular-superoxide dismutase to the endothelial cell surface. FEBS Lett 2000;486:159-62.
101. Guemori L, Arthur Y, Herbeth B, et al. Biological variability of superoxide dismutase, glutathione peroxidase, and catalase in blood. Clin Chem 1991;37:1932-7.
102. Moat SJ, Bonham JR, Cragg RA, et al. Elevated plasma homocysteine elicits an increase in antioxidant enzyme activity. Free Radic Res 2000;32:171-9.
103. Wilcken DEL, Wang XL, Adachi T, et al. Relationship between homocysteine and superoxide dismutase in homocystinuria: possible relevance to cardiovascular risk. Arterioscler Thromb Vasc Biol 2000;20:1199-202.
104. Loscalzo J. The oxidant stress of hyperhomocysteinemia. J Clin Invest 1996;98:5-7.
105. Karbownik M, Lewinski A, Reiter RJ. Anticarcinogenic actions of melatonin which involve antioxidative processes: comparison with other antioxidants. Int J Biochem Cell Biol 2001;33:735-53.
106. Kilic E, Ozdemir YG, Bolay H, et al. Pinealectomy aggravates and melatonin administration attenuates brain damage in focal brain ischemia. J Cereb Blood Flow Metab 1999;19:511-6.
107. Reiter RJ, Guerrero JM, Escames G, et al. Prophylactic actions of melatonin in oxidative neurotoxicity. Ann NY Acad Sci 1997;825:70-8.
108. Okatani Y, Wakatsuki A, Reiter RJ. Melatonin counteracts potentiation by homocysteine of KCL-induced vasoconstriction in human umbilical artery: relation to calcium influx. Biochem Biophys Res 2001;280:940-4.
109. Kahn NN, Bauman WA, Sinha AK. Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury. Proc Natl Acad Sci USA 1996;93:245-9.